MedTrace Logo

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

NCT05121363 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2021-11-30

No results posted yet for this study

Summary

A clinical trial to evaluate TQB2858 injection combined with Anlotinib Hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial carcinoma

Conditions

  • Endometrial Carcinoma

Interventions

DRUG

TQB2858 injection

TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein

DRUG

Anlotinib Hydrochloride capsules

Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2023-05-31
Completion
2023-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121363 on ClinicalTrials.gov